EcoDrugPlus

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 6

Ensembl ID : ENSOJAG00000010714
Gene Symbol: CACNG6
1 Cross references
176 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 7

Ensembl ID : ENSOJAG00000007370
Gene Symbol: CACNG7
1 Cross references
143 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 7

Ensembl ID : ENSOJAG00000010701
Gene Symbol: CACNG7
1 Cross references
187 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 8

Ensembl ID : ENSOJAG00000010709
Gene Symbol: CACNG8
1 Cross references
159 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSOJAG00000010675
Gene Symbol: CACNA1A
1 Cross references
186 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSOJAG00000022196
Gene Symbol: CACNA1D
1 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSOJAG00000018942
Gene Symbol: CACNA1E
1 Cross references
207 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSOJAG00000010134
Gene Symbol: CACNA1E
1 Cross references
214 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSOJAG00000021236
Gene Symbol: CNR1
1 Cross references
134 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSOJAG00000022174
Gene Symbol: CNR1
1 Cross references
150 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSOJAG00000008565
Gene Symbol: CNR2
1 Cross references
191 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSOJAG00000018022
Gene Symbol: CA12
1 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).